ESR1 and breast cancer: However, the rate of mutations may increase in advanced TNBC, reflecting the high rate of observed PIK3CA mutations in initially ER+ breast cancer, which relapses, loses ER expression and becomes secondary TNBC while retaining the high rate of activating PI3Ks.